预约演示

更新于：2025-05-07

Corporacion Sanitaria Parc Tauli

私营公司|Spain

更新于：2025-05-07

概览

关联

174

项与 Corporacion Sanitaria Parc Tauli 相关的临床试验

NCT06597929

/ Not yet recruitingN/AIIT

The Effectiveness of Moderate-vigorous Intermittent Lifestyle Physical Activity and Health Education to Increase Intense Physical Activity in Stroke Survivors: a Pragmatic Randomised Controlled Trial (MV-ILPA-stroke)

Stroke is the leading cause of disability in Spain. Additionally, it is the second leading cause of death in women and the third in both sexes. Regular physical activity (PA) helps prevent and manage stroke. It also helps with hypertension, maintains a healthy body weight, and improves mental health, quality of life, and well-being. PA plays a prominent role in inpatient care after stroke. However, stroke survivors become more sedentary when discharged from the hospital. They have muscle weakness, reduced balance, and fatigue. Consequently, PA levels of community-dwelling post-stroke individuals remain lower than their age-matched counterparts. Continued PA can help this population maintain and improve physical function, and reduce long-term functional limitations, and mortality risk.

开始日期2025-04-01

申办/合作机构

Universitat Internacional de Catalunya

[+1]

NCT06900335

/ CompletedN/AIIT

Characterization of the Functional Connectome in Prader-Willi Syndrome: Integrating Neuroimaging and Artificial Intelligence to Assess the Impact of Physiological and Therapeutic Interventions

The goal of this observational study is to explore brain network changes and identify patterns related to hyperphagia, hormonal treatment effects, and cognitive deficits in adults with Prader-Willi Syndrome (PWS). The main questions it aims to answer are:
* How are brain connectivity patterns altered in PWS patients compared to healthy and obese controls?
* How do brain network changes relate to hyperphagia and the response to growth hormone therapy?
Researchers will compare PWS patients to healthy and obese controls to see if there are significant differences in brain network connectivity before and after meals and growth hormone therapy. Ultimately, researchers will try to develop predictive models of treatment outcomes using AI and machine learning.

开始日期2025-03-01

申办/合作机构

Corporacion Sanitaria Parc Tauli

NCT06873360

/ Not yet recruitingN/AIIT

Design of a Medical Device for Oxaliplatin-Induced Peripheral Neuropathy Considering the Patient's Voice in Gastrointestinal Cancer

This is an observational study related to a medical device designed for the prevention of oxaliplatin-induced peripheral neuropathy (OIPN) in patients with gastrointestinal cancer. The primary objective is to collect data through interviews with patients experiencing OIPN symptoms to co-design the medical device prototype, incorporating the patient's perspective. Additionally, the study aims to identify clinical and usability patterns that will help optimize the design of a future clinical investigation assessing the safety and efficacy of the final device.

开始日期2025-03-01

申办/合作机构

Corporacion Sanitaria Parc Tauli

100 项与 Corporacion Sanitaria Parc Tauli 相关的临床结果

登录后查看更多信息

0 项与 Corporacion Sanitaria Parc Tauli 相关的专利（医药）

登录后查看更多信息

115

项与 Corporacion Sanitaria Parc Tauli 相关的文献（医药）

2025-06-01·The Lancet Regional Health - Europe

Safety and efficacy of combined portal and hepatic vein embolisation in patients with colorectal liver metastases (DRAGON1): a multicentre, single-arm clinical trial

Article

作者: Grünhagen, Dirk J ; Imani, Farshad ; Andorrà, Esteban Cugat ; Seeger, Nico ; Moragues, Jaume Sampere ; Herrero, Eric ; Dewulf, Maxime J L ; Serenari, Matteo ; Billingsley, Kevin G ; Arntz, Pieter J W ; van Baardewijk, Laurens J ; Leclercq, Wouter K G ; Fretland, Åsmund A ; Lindsay, Richard ; Vogl, Thomas J ; Bemelmans, Marc H A ; Hoffmann, Martin H ; Ryan, Stephen ; Xudong, Qu ; Navinés-López, Jordi ; Erdmann, Joris I ; van Dam, Ronald M ; Korenblik, Remon ; Baclija, Ivan ; Wang, Xiaoying ; Zijlstra, IJsbrand A J ; Schnitzbauer, Andreas ; Wohlgemuth, Walter A ; Udupa, Venkatesha ; Delle, Martin ; Fouraschen, Suomi M G ; De Cobelli, Francesco ; Carling, Ulrik ; Criado, Eva ; Björnsson, Bergthor ; Macdonald, Andrew ; Suarez, Yiliam Fundora ; Vass, David G ; Díaz-Nieto, Rafael ; Detry, Olivier ; Madoff, David C ; Pieterman, Kay J ; Davis, Rob ; Heil, Jan ; Binkert, Christoph A ; Metrakos, Peter ; Serrablo, Alejandro ; Primrose, John N ; Aldrighetti, Luca A ; Ridouani, Fourat ; Kleeff, Jörg ; Borel Rinkes, Inne H M ; Stavrou, Gregor A ; Kalil, Jennifer ; Moelker, Adriaan ; Smits, Jens ; de Boer, Marieke T ; Olde Damink, Steven W L ; Sparrelid, Ernesto ; Gelabert, Arantxa ; Sarriá, Luis ; Kollmar, Otto ; Modi, Sachin ; Chan, Benjamin K Y ; Bokkers, Reinoud P H ; Gruenberger, Thomas ; Schadde, Erik ; De Boo, Diederick W ; Muños, Fernando Gómez ; Valenti, David ; van der Leij, Christiaan ; Spuentrup, Elmar ; Winkens, Bjorn ; Martel, Guillaume ; Cappelli, Alberto ; Sandström, Per A ; Kingham, T Peter ; Gerard, Laurent ; Borobia, Francisco G ; Gobardhan, Paul D ; Croagh, Daniel ; Breitenstein, Stefan ; Smits, Maarten L J ; James, Sinéad ; Tasse, Jordan C

BackgroundMajor liver resection is often required for complete clearance of colorectal liver metastases (CRLM). Patients with insufficient future liver remnant (FLR) volume/function are at high risk of post-hepatectomy liver failure (PHLF) and require FLR hypertrophy-inducing procedures to enable safe resection. The most recent variant of these procedures is combined portal and hepatic vein embolization (PVE/HVE). The DRAGON 1 trial evaluates the safety and efficacy of PVE/HVE, while assessing recruitment potential for the DRAGON 2 randomized trial.MethodsDRAGON 1 is a prospective, single-arm, international, multicenter trial. Patients with upfront unresectable CRLM due to a small FLR were included. The primary outcome was the ability of centers to recruit three patients and perform PVE/HVE and liver resection without 90-day mortality. Secondary outcomes included recruitment capacity, PVE/HVE technical details, FLR volume changes, complications, and resection rates. The study is registered at ClinicalTrials.gov, identifier: NCT04272931.FindingsIn total, 102 patients were included from 43 centers. Twenty-four centers (24/43 = 56%) recruited three or more patients, and 20 centers (20/43 = 47%) achieved this without 90-day mortality. Of 96 patients undergoing PVE/HVE, no post-embolization mortality occurred, though major complications were reported in two patients. Resection was completed in 86 patients (86/96 = 90%), with seven patients (7/86 = 8%) dying within 90 days. PHLF grade B/C (International Study Group of Liver Surgery criteria) occurred in 19 patients (19/86 = 22%).InterpretationDRAGON 1 demonstrates that PVE/HVE is safe, with no embolization-related mortality, low morbidity, and high resection rates in upfront unresectable CRLM.FundingThe Dutch Cancer Society, National Institute for Health and Care Research UK, Maastricht UMC+, Abbott Laboratories and Guerbet.

2023-10-01·Pediatric Pulmonology

Characteristics and management of patients with SARS‐CoV2 infection admitted to pediatric intensive care units: Data analysis of the Spanish national multicenter registry

Article

作者: Belda Hofheinz, Sylvia ; Slöcker Barrio, María ; Jiménez Olmos, Ainhoa ; Holanda Peña, Maria Soledad ; García-Salido, Alberto ; Rey Galan, Corsino ; Huidobro Labarga, Beatriz ; González Navarro, Pablo ; Martínez Padilla, Carmen ; Oulego-Erroz, Ignacio ; Roca Pascual, David ; Hernández Yuste, Alexandra ; Cuervas-Mons Tejedor, Maite ; Rodríguez Rubio, Miguel ; Sanchíz Cárdenas, Sonia ; Morteruel Arizcuren, Elvira ; García-Besteiro, Maria ; Bermúdez Barrezueta, Lorena ; Guitart Pardellans, Carmina ; Cortés, Rafael González ; Calvo Monge, Cristina ; de Carlos Vicente, Juan Carlos

AbstractIntroductionThe purpose of this study is to describe the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV2) disease characteristics and management in children admitted to the pediatric intensive care units (PICU).MethodsThe present study was based on a national multicentric prospective registry including PICU patients with SARS‐CoV2 infection or symptoms of multisystem inflammatory syndrome in children (MIS‐C).ResultsA total of 298 patients were admitted to 41 different Spanish PICUs. A total of 76% of them were previously healthy. The most frequent manifestation was MIS‐C (69.8%). On admission, 59.4% of patients did not have respiratory distress, and only 17.4% needed conventional mechanical ventilation (MV). The need for MV was associated with age (incidence rate ratios [IRR] 1.21, p < .012), pediatric sequential organ failure assessment score (p‐SOFA) Score (IRR 1.12, p = .001), and need for transfusion (IRR 4.5, p < .004) in MIS‐C patients, and with vasoactive drug use (IRR 2.73, p = .022) and the diagnosis of acute respiratory distress syndrome (IRR 2.83, p = .018) in patients admitted for other reasons. During the first day of admission, 56% of patients met shock criteria and 50.7% needed vasoactive drugs. In MIS‐C patients, their use was associated with higher p‐SOFA score (IRR 1.06, p < .001) and with the diagnosis of shock (IRR 5.78, p < .001). In patients without MIS‐C, it was associated with higher p‐SOFA score (IRR 1.05, p = .022). The mortality rate was 3%, being lower in MIS‐C patients compared to patients admitted for other reasons (0.5% vs. 9.4%, p < .001). It was also lower in previously healthy patients compared to patients with previous comorbidities (0.9% vs. 9.7%, p < .001).ConclusionsSevere SARS‐CoV2 infection is uncommon in the pediatric population. In our series, respiratory distress was rare, being MIS‐C the most frequent cause of PICU admission related to SARS‐CoV2. In most cases, the course of the disease was mild except in children with previous diseases.

2023-06-01·Journal of Clinical Oncology

Impact of WNT/B-catenin alterations and metastasis location among patients with metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI) combinations.

作者: Vega, Sharela ; Baraibar, Iosune ; Alonso, Guzman ; Tabernero, Josep ; Salva, Francesc ; Garcia, Ariadna ; Navarro Garces, Victor ; Ros Montañá, Javier ; Garralda, Elena ; Saoudi Gonzalez, Nadia ; Bueno, Sergio ; Saavedra, Omar ; Elez, Elena ; Rodríguez Castells, Marta ; Vivancos, Ana ; Comas, Raquel

3573 Background: Emerging evidence suggests that WNT mutations and liver/peritoneal metastases in mCRC may have an immunosuppressive role that could affect ICI activity. Aim: To evaluate the impact of WNT alterations and liver/peritoneal metastasis among patients with mCRC treated with ICi. Methods: Patients from Vall d’Hebron Hospital, with mCRC treated with ICI from 2017-2022 were included. WNT alterations (APC, AXIN1/2, CTNNB1, FBXW7, EPHB2, RNF43 and SOX9) were evaluated using NGS (tissue). Clinical outcomes were calculated using survival Kaplan-Meier curves. Patients' characteristics were collected retrospectively. Results: Overall, 104 patients were included (66 MSI patients and 38 MSS patients). Among MSI patients, median age was 63 years (22-95), with 53% female, and 64% of patients received immunotherapy in 1st or 2nd line. Regarding tumor characteristics, 72% were right-sided and 82% harbored WNT alterations. 75% of patients presented with liver/peritoneal metastases. Patients with WNT mutations and peritoneal/liver metastases exhibit lower ORR (46% vs 57% p 0.5 and 45% vs 75%, p 0.03 respectively). Peritoneal/liver metastases were associated with lower PFS (HR 3.6 CI95% 1.27-10.24 p 0.02 respectively). Overall, tumors with WNT pathway alterations tend to have shorter PFS and OS. Liver metastases were associated with lower OS (NR vs 34 months HR 2.49 CI95% 1.01-6.17 p 0.05). Table summarizes outcomes. Among MSS patients, median age was 57 years (41-75), with 25% female and 92% of patients receiving immunotherapy > = 3rd line. Regarding tumor characteristics, 78% were left-sided and 90% harboured WNT alterations. 79%, of patients presented with liver or peritoneal metastases. WNT mutations were not associated with ORR, patients without liver/peritoneal metastases tend to have higher ORR (12.5% vs 3.3% p 0.335). Patients with WNT alterations had worse PFS (9.23 vs 1.87 months, p 0.12), and liver metastases were associated with lower PFS (6.98 vs 1.79 months HR 2.87 CI95% 1.17-7.09 p:0.02). Regarding OS, tumors harboring WNT alterations have shorter OS (8.4 vs 12 months p 0.63). The presence of liver or peritoneal metastases was associated with lower OS (NR vs 7.85 months HR 3.69 CI95% 1.09-12.55 p: 0.04). Conclusions: In our cohort, WNT pathway mutations, and liver metastases were associated with worse ORR, PFS, and OS regardless of MSI status. These findings need further validation in a prospective cohort. [Table: see text]

100 项与 Corporacion Sanitaria Parc Tauli 相关的药物交易

登录后查看更多信息

100 项与 Corporacion Sanitaria Parc Tauli 相关的转化医学

登录后查看更多信息